Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

PMID:
16710024
2.

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.

Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, Reilly RM.

Nucl Med Biol. 2005 Jan;32(1):51-8.

PMID:
15691661
3.

Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.

Cornelissen B, Kersemans V, Burvenich I, Oltenfreiter R, Vanderheyden JL, Boerman O, Vandewiele C, Slegers G.

Nucl Med Commun. 2005 Feb;26(2):147-53.

PMID:
15657509
4.

Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.

Schechter NR, Wendt RE 3rd, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK.

J Nucl Med. 2004 Oct;45(10):1683-7.

5.

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG.

Br J Pharmacol. 2004 Sep;143(1):99-106.

6.

Lighting up tumors with receptor-specific optical molecular probes.

Achilefu S.

Technol Cancer Res Treat. 2004 Aug;3(4):393-409. Review.

PMID:
15270591
7.

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM.

Nat Biotechnol. 2004 Jun;22(6):701-6.

8.

Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.

Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C.

Cancer Res. 2003 Nov 15;63(22):7870-5.

9.

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

Grünwald V, Hidalgo M.

J Natl Cancer Inst. 2003 Jun 18;95(12):851-67. Review.

PMID:
12813169
10.

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.

Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R 3rd, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA.

Anticancer Drugs. 2003 Jan;14(1):49-56.

PMID:
12544258
11.

Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging.

Ntziachristos V, Bremer C, Weissleder R.

Eur Radiol. 2003 Jan;13(1):195-208. Review.

PMID:
12541130
12.

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L.

Cancer Res. 2002 Dec 15;62(24):7350-6.

13.
14.

Biology of HER2 and its importance in breast cancer.

Yarden Y.

Oncology. 2001;61 Suppl 2:1-13. Review.

PMID:
11694782
15.
16.

The basic biology of HER2.

Rubin I, Yarden Y.

Ann Oncol. 2001;12 Suppl 1:S3-8. Review.

PMID:
11521719
17.

Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands.

Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grötzinger C.

Nat Biotechnol. 2001 Apr;19(4):327-31.

PMID:
11283589
18.

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.

Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, Vallis K, Gariépy J.

J Nucl Med. 2000 May;41(5):903-11.

19.

Growth factor synthesis and human breast cancer progression.

Ethier SP.

J Natl Cancer Inst. 1995 Jul 5;87(13):964-73. Review.

PMID:
7629883
20.

Predictive value of EGF receptor in breast cancer.

Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U.

Lancet. 1988 Nov 26;2(8622):1258. No abstract available.

PMID:
2903994

Supplemental Content

Support Center